自本公告发布之日起15个交易日后的3个月内，湖州赛瀚拟通过集中竞价交易减持不超过940.99万股， 即不超过公司总股本的1%。 珍宝岛（603567）(603567.SH)发布公告，自本公告发布之日起15个交易日后的3个月内，亳州郡泽方隆 拟通过集中竞价交易或大宗交易方式合计减持不超过2822.99万股，即不超过公司总股本的3%。 ...

自本公告发布之日起15个交易日后的3个月内，湖州赛瀚拟通过集中竞价交易减持不超过941万股,即不 超过公司总股本的1%。 格隆汇8月19日丨珍宝岛(603567.SH)公布，自本公告发布之日起15个交易日后的3个月内，亳州郡泽方 隆拟通过集中竞价交易或大宗交易方式合计减持不超过2822.99万股,即不超过公司总股本的3%。其中， 以集中竞价方式减持不超过941万股，即不超过公司股本总额的1%，以大宗交易方式减持不超过 1881.99万股，即不超过公司股本总额的2%。 ...

转自：证券时报 人民财讯8月19日电，珍宝岛(603567)8月19日晚间公告，持股5.93%的亳州郡泽方隆股权投资中心（有 限合伙）拟通过集中竞价交易或大宗交易方式合计减持不超过2822.99万股,即不超过公司总股本的3%。 持股5.01%的湖州赛瀚股权投资合伙企业（有限合伙）拟通过集中竞价交易减持不超过941万股,即不超 过公司总股本的1%。 ...

天眼查商业履历信息显示，黑龙江珍宝岛药业股份有限公司，成立于1996年，位于鸡西市，是一家以从 事医药制造业为主的企业。企业注册资本94114.0609万人民币，实缴资本36000万人民币。公司法定代 表人为闫久江。 通过天眼查大数据分析，黑龙江珍宝岛药业股份有限公司共对外投资了27家企业，参与招投标项目2132 次，知识产权方面有商标信息133条，专利信息204条，此外企业还拥有行政许可229个。 来源：金融界 金融界消息 截至2025年8月14日收盘，珍宝岛（603567）报收于12.28元，下跌2.92%，换手率1.35%， 成交量12.70万手，成交金额1.59亿元。 资金流向方面，今日主力资金净流出1236.64万元，占比成交额7.78%。其中，超大单净流出1170.55万 元、占成交额7.37%，大单净流出66.09万元、占成交额0.42%，中单净流出流入319.11万元、占成交额 2.01%，小单净流入917.53万元、占成交额5.78%。 珍宝岛最新一期业绩显示，截至2025一季报，公司营业总收入4.69亿元、同比减少58.03%，归属净利润 7529.54万元，同比减少74.33%，扣非净利 ...

Group 1 - The epidemic prevention and control work for Chikungunya fever in Guangdong has entered a critical stage, with Zhenbaodao Pharmaceutical quickly activating an emergency response mechanism to allocate 100 cases of Fufang Qilan Oral Liquid to support frontline epidemic prevention efforts in Foshan [1][3] - The donation of Fufang Qilan Oral Liquid by Zhenbaodao Pharmaceutical is seen as a demonstration of corporate social responsibility, providing strong material support for the control of mosquito-borne diseases in Foshan and boosting confidence in combating the epidemic [3] - Zhenbaodao Pharmaceutical emphasizes the importance of traditional Chinese medicine (TCM) in epidemic prevention, citing the historical understanding of epidemic diseases and the unique perspective it offers for modern epidemic control [3][4] Group 2 - Chikungunya fever is a mosquito-borne infectious disease that has spread to over 100 countries globally, with some patients experiencing prolonged joint pain for months to years after recovery, and there is currently no specific treatment available [3] - The Fufang Qilan Oral Liquid, derived from the classical TCM formula "Yinqiao San," is designed to align with the treatment principles for Chikungunya fever, focusing on clearing heat and detoxifying [4] - Zhenbaodao Pharmaceutical has demonstrated its commitment to public health by donating medicines and supplies during multiple public health events, showcasing its experience in emergency response and dedication to safeguarding national health [4]

Group 1 - The company announced a price adjustment for the exchangeable bonds issued by its controlling shareholder, Heilongjiang Chuangda Group Co., Ltd. [1][2] - The first phase of the exchangeable bonds, with a total issuance of 910 million yuan and a term of 3 years, was completed on April 11, 2023 [1] - The second phase of the exchangeable bonds, with a total issuance of 90 million yuan and a term of 3 years, was completed on June 28, 2023 [2] Group 2 - The company’s 2024 profit distribution plan includes a cash dividend of 1.50 yuan per 10 shares, totaling approximately 141.13 million yuan [3] - The adjusted cash dividend per share, after considering the total share capital dilution, will be 0.15 yuan per share [3] - The record date for the profit distribution is set for August 19, 2025, with the ex-dividend date and cash dividend payment date on August 20, 2025 [3] Group 3 - The adjustment of the exchange price for the bonds is based on the company's profit distribution and follows specific formulas outlined in the bond issuance prospectus [4][5] - The exchange price for the first phase bond will be adjusted from 13.50 yuan to 13.35 yuan per share, while the second phase bond will be adjusted from 10.69 yuan to 10.54 yuan per share [5] - The controlling shareholder has sufficient stock available for the exchange after the price adjustments [5]

证券代码：603567 证券简称：珍宝岛 公告编号：临 2025-063 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 根据《黑龙江创达集团有限公司 2023 年面向专业投资者非公开发行可交换 公司债券（第一期）募集说明书》（以下简称"第一期募集说明书"）和《黑龙江 创达集团有限公司 2023 年面向专业投资者非公开发行可交换公司债券（第二期） 募集说明书》（以下简称"第二期募集说明书"）的约定，当标的股票发生派送股 票股利、转增股本、增发新股或配股、派送现金股利等情况使标的股票价格发生 变化时，将按下述公式进行换股价格的调整（保留小数点后两位，最后一位四舍 五入）： 派送股票股利或转增股本：P1=P0/（1+n）； 增发新股或配股：P1=（P0+A×k）/（1+k）； 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非 ...

Group 1 - The company announced a cash dividend distribution of 0.15 yuan per share for the fiscal year 2024, approved at the annual shareholders' meeting on June 25, 2025 [2][4] - The total cash dividend distribution amounts to approximately 141.13 million yuan, based on a total share capital of 940,996,515 shares, excluding shares held in the repurchase account [4][6] - The dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the record date [3][4] Group 2 - The company plans to postpone the completion dates for two fundraising investment projects: the "Jixi Branch Phase III Construction Project" to August 2026 and the "Traditional Chinese Medicine Material Processing Project" to October 2026 [11][22] - The postponement is due to external environmental factors affecting project progress, and the company aims to enhance the quality of the investment projects [22][25] - The board of directors approved the postponement during the meeting held on August 11, 2025, and the decision will be submitted for approval at the upcoming shareholders' meeting [26][36] Group 3 - The company intends to provide a guarantee for its wholly-owned subsidiary, Heilongjiang Zhenbaodao Medical Trade Co., Ltd., for bank financing up to 400 million yuan [29][30] - The guarantee is deemed necessary to support the subsidiary's operational needs, with the board considering the risk to be manageable [35][36] - The total amount of external guarantees provided by the company is 1.791 billion yuan, which accounts for 22.96% of the latest audited net assets [37]

Summary of Key Points Core Viewpoint - The company, Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., is providing a guarantee of up to RMB 400 million for its wholly-owned subsidiary, Heilongjiang Zhenbaodao Medical Trading Co., Ltd., to support its bank financing needs [1][5]. Group 1: Guarantee Details - The total guarantee amount is RMB 400 million, with an actual guarantee balance of RMB 345 million [1]. - The guarantee is subject to approval at the company's second extraordinary general meeting in 2025 [2]. - The guarantee will be effective from the date of approval until the annual general meeting in 2025 [4]. Group 2: Financial Overview of the Subsidiary - The subsidiary, Heilongjiang Zhenbaodao Medical Trading Co., Ltd., has total assets of RMB 322.91 million as of the first quarter of 2024 and RMB 345.39 million for the audited year [4]. - The total liabilities are RMB 248.88 million for the first quarter of 2024 and RMB 273.83 million for the audited year [4]. - The net profit for the first quarter of 2024 is RMB 2.48 million, while the audited net profit for the year is RMB 25.83 million [4]. Group 3: Board's Opinion and Risk Assessment - The board believes that the guarantee is necessary and reasonable, as the subsidiary has sufficient capacity to repay its debts [5]. - The company has a total external guarantee amount of RMB 1.791 billion, which is 22.96% of the latest audited net assets [5]. - There are no overdue guarantees, and the company has not provided guarantees to controlling shareholders or related parties [5].

Core Viewpoint - The company has announced a delay in the expected operational status of two fundraising investment projects, extending the timeline for the "Jixi Branch Phase III Project" to August 2026 and the "Traditional Chinese Medicine Material Processing Project" to October 2026 [1][4][10] Fundraising Overview - The company raised a total of RMB 1,237,999,917.28 through a non-public offering of 92,803,592 shares at a price of RMB 13.34 per share, with a net amount of RMB 1,217,240,132.22 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, and a three-party/four-party supervision agreement has been signed [1] Investment Project Details - The company has made adjustments to its fundraising investment projects due to changes in market conditions and policy adjustments, including the termination of certain sub-projects and reallocating funds to other projects [2][3] - The "Jixi Branch Phase III Project" involves the construction of a chemical synthesis workshop and related facilities, with construction progress affected by industry policies and competition [8] Delay Reasons and Measures - The delays in project timelines are attributed to construction progress lagging behind the original schedule, necessitating a cautious review and adjustment of the expected operational status [6][9] - The company plans to implement measures to ensure compliance and efficient use of the raised funds, including strict supervision of project progress [9] Approval Process - The delay in the investment projects was approved by the company's board of directors, following necessary procedures and compliance with relevant regulations [10]